Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products are given as single ascending doses to healthy adult subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05349435
Study type Interventional
Source Liminal BioSciences Ltd.
Contact
Status Terminated
Phase Phase 1
Start date May 13, 2022
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05842837 - A Non-Interventional Post-Authorization Study of Carbaglu for the Treatment of Hyperammonemia Due to MMA and PA
Completed NCT03947034 - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Completed NCT06178718 - A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules Phase 1
Recruiting NCT05040178 - An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Withdrawn NCT00279851 - Blood Sugars in Children With Idiopathic Seizures.
Completed NCT06135675 - Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia Phase 1/Phase 2